Metastatic malignant melanoma with neuroendocrine differentiation: a case report and review of the literature

Table 1 Immunohistochemical details of the metastatic lesions

			Immunohistochemical markers
Time point	Tissue investigated	Procedure	CgA	SYP	CD56	INSM1	ISLET1	Cyto-keratins	Vimentin	Melan A	HMB45	SOX10	Diagnosis
April 2019	Chest wall	Core-needle biopsy	–	+ (100%)	+ (100%)	+ (100%)	+ (10%)	– *	+ (100%)	–	–	n.d.	NEC
June 2019	Femur	Surgical excision	–	+ (15%)	+ (100%)	n.d.	n.d.	–	+ (100%)	+ (30%)	+ (30%)	+ (100%)	MM-NE

CgA chromogranin A, HMB45 human melanoma black 45, INSM1 insulinoma-associated protein 1, ISLET1 ISL LIM homeobox 1, Melan A melanoma antigen, MM-NE malignant melanoma with neuroendocrine differentiation, n.d. not determined, – negative staining, NEC neuroendocrine carcinoma, SYP synaptophysin
*Focal cytokeratin OSCAR immunoreactivity noted in few tumor cells – uncertain significance

ISSN: 1752-1947